At Cathie Wood’s Ark Invest may have had a disappointing 2021, but the fund’s purchases/liquidations are still closely monitored by investors. On Friday, ETFs managed by Ark Invest picked up shares of two healthcare companies.
Biology with a twist: Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and genomics company that has developed a DNA synthesis platform.
The company’s platform uses new technology to make synthetic DNA by writing DNA onto a silicon chip. This technology is used to manufacture a wide range of synthetic DNA products, including synthetic genes, tools for the preparation of next generation sequencing (NGS) and antibody libraries for the discovery and development of medications.
Twist Biosciences announced better than expected first quarter results in February, thanks to the strong performance of SynBio. Company expects NGS and biopharma segments to drive growth in 2022, SVB Leerink analyst Puneet Souda said following the company’s presentation at the SVB Leerink Global Healthcare conference.
Ark Invest bought 25,704 shares of the company on Friday through its ARK Innovation ETF (NYSE: ARKK) and ARK Genomic Revolution ETF (fund (BATS: ARKG).
Analysts’ average price target for Twist Bioscience shares is $75.83, suggesting an upside of more than 43% from current levels.
Related Link: Why Morningstar Downgrades Cathie Wood’s ARK Innovation ETF to Negative
SomaLogic – A Health Technology Company: SomaLogic, Inc., based in Colorado. (NASDAQ: SLGC) is a protein biomarker discovery and clinical diagnostics company. The Company’s products include laboratory tests named SomaScan and SomaSignal, which help collect proteomic information from patients and monitor their physiological states.
Proteomics refers to the applications of technologies for the identification and quantification of overall proteins present in a cell, tissue or organism.
SomaLogic’s products are also used by researchers to analyze biological samples for protein biomarker signatures, which in turn can be used in drug discovery.
Ark Invest, through its ARKQ, bought 242,467 shares of the company on Friday.
Analysts’ average price target of $15.50 for SomaLogic shares suggests there is room for a nearly 100% upside.
Twist Biosciences closed Friday’s session up 7.15% at $52.91 and SomaLogic was down 1.12% at $7.93.
Related Link: Attention Biotech Investors: Mark Your Calendar for April PDUFA Dates
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.